aaxn_Ex99

Free access to Axon Citizen cloud software, to enable social distancing, for the rest of 2020. After this offering, we saw agency usage of Citizen climb by 35%.

“Our officers were excited to hear that now, they can send the link directly to the citizen from their city-issued smartphones,” said Bakersfield Police Department Sgt. Uriel Pacheco. “The implementation has not only saved our officers time, but reduced the need for interaction when collecting digital evidence.”

A partnership with the National Police Foundation where Axon has committed over $1.7 million, plus the efforts of our operations and supply chain, in sourcing personal protective equipment (PPE) for first responders. This effort, which allows the public to donate, has been trending on social media with the hashtag, #gotyoucovered, and received a mention on Twitter from Vice President Mike Pence.

An online support center for our customers. https://www.axon.com/covid-19-support-center

The Axon Accelerate user conference in Nashville in early August is going virtual. Axon’s annual user conference has grown to be the largest technology-focused conference in law enforcement. We're looking forward to delivering immersive engagement to educate our customers about our products in an online and VR format.

Employee safety & manufacturing: Axon takes health and safety seriously, and our entire mission is to protect life. Just days after our last quarterly update, we curbed all non-essential employee travel and then quickly moved to support our information workers to do their jobs from home.

Our customers are counting on us to deliver TASER 7 and Axon body cameras. We are proud to be able to ensure that first responders have the tools they need to keep society safe and orderly. Early on in the US outbreak, Axon management was in discussions with local authorities and our Board, particularly Dr. Richard Carmona, the former US Surgeon General, and determined that the best course of action was to keep our critical manufacturing lines open to satisfy customer demand.

We’ve also taken steps to mitigate contamination risk in our facilities. This includes staggering work schedules, proactively sending high-risk groups home with pay, providing access to a registered nurse on site and increasing our cleaning standards to a level that exceeds CDC guidance.

Supply chain: We have adapted well to ongoing challenges. In 2019, we took action to diversify our supply chain and global manufacturing footprint. Those initiatives positioned us well to handle COVID-19, enabling us to produce and ship our critical core products with little to no interruption. While we feel confident in our preparations, there are still many unforeseen challenges that lay ahead. We continue to manage through supply chain disruptions, finding alternate sources when available or working with foreign regulators to ensure that our suppliers can provide parts. We elevated our inventory build in Q1 2020 and are continuing to do so over the course of 2020, which is a proactive approach to building safety stock in an effort to minimize shipping disruptions. We are committed to working through challenges as they arise to support our customers and deliver mission critical equipment.

Shareholder engagement: We have pivoted our shareholder engagement to a virtual format. Our annual meeting, scheduled for May 29, will be held online at www.virtualshareholdermeeting.com/AAXN2020, and we will be participating in several upcoming investor conferences utilizing video conferencing. All investor materials and events are available at investor.axon.com.

Progress on our core initiatives:

Axon Dispatch is officially powering 911—we are live in Maricopa, Ariz., with our first paid customer: At 6 am on April 19, Arizona’s City of Maricopa Police Department moved over from a competitor and went live on Axon’s cloud-based Computer Aided Dispatch (CAD) solution to power their 911 incident response. We are proud of our engineering, product, customer support and professional services teams for delivering this key milestone, and excited that Axon is now officially powering mission-critical 911 infrastructure in a US city. Particularly during COVID-19, this deployment required intense attention to detail, with more than two dozen people on Zoom and a reduced, scrappy onsite team. We internally live-streamed the deployment and coordinated among our staff and with the agency using our own situational awareness tools: Axon Body 3 camera hardware and Axon Aware

live-streaming cloud software. Axon’s ability to deliver a key new product, on schedule, in the middle of a global pandemic, is a testament to Axon’s adaptability in the face of challenges and the dedication of our talented employees. It’s also a testament to our customer, the City of Maricopa Police Department, led by Chief Steve Stahl and his relentless commitment to modern policing and innovation on behalf of the citizens he protects.

Our SaaS strategy is driving a net revenue retention of 120%: We drive adoption of our cloud software solutions through integrated bundling, which creates a flywheel effect of compounding benefits for customers. Officer Safety Plan 7+, our highest-tier bundle, combines our latest generation TASER devices and body cameras with a growing suite of cloud software, including the Axon Records records management system (RMS) and the Axon Aware live-streaming and real-time situational awareness platform. We are seeing major cities upgrading their subscriptions at individual net dollar retention rates of 150% to 300% to take advantage of our growing suite of productivity and digital evidence management tools. And, because our agency customers sign up for five-to-ten-year subscriptions, we continue to experience low annual churn. These factors have combined to sustain a dollar-based net revenue retention of about 120% across our entire SaaS customer base over the past two quarters. (This SaaS metric purposely excludes the hardware portion of customer subscriptions. We further define this metric under “Statistical Definitions.”)

Flock Safety strategic partnership augments camera sensor strategy: In Q1 2020, we entered into a commercial partnership with Flock Safety, a venture-backed provider of advanced security for neighborhoods and law enforcement. Our relationship with Flock is three-fold: We are a channel partner, an integration partner, and a minority investor. We intend to make it easier and more cost effective for police departments to deploy a network of fixed and mobile automated license plate reader (ALPR) sensors by integrating and bundling Flock’s solution alongside our upcoming Axon Fleet 3 in-car solution. Both Fleet 3 and Flock are built with an ethical design framework, and seek guidance from Axon’s independent AI Ethics Board. We are excited that through our Flock partnership, our camera sensor offerings now include body-worn, in-car and fixed pole cameras.

Increased momentum in corrections: Axon is now engaged with more than 10 state departments of corrections, including the five most populous states in the country — California, Texas, Florida, New York and Pennsylvania — which are either purchasing our products, undergoing trials at scale, or seeking to have budget discussions and command demonstrations of TASER devices, Axon body cameras and Axon Cloud software. In the US, there are about 450,000 correctional officers and about 92,000 probation and parole officers, and we estimate that TASER device and Axon body camera penetration among them is minimal. State departments of corrections are seeing dramatic reductions in violence following the deployment of TASER devices, Axon body cameras, or both. As one example, within a recent webinar sponsored by the Department of Justice, Bureau of Justice Assistance, the Florida Department of Corrections shared results of a 1.5-year pilot deploying TASER devices and Axon body-worn cameras, which resulted in a 42% reduction in staff assaults, 51% reduction in uses of force in the general population, and a 70% reduction in excessive force complaints.

Summary of Q1 2020 results:

Revenue grew 27% year over year to $147 million, with strength driven by our Software & Sensors product segment, which grew 41% year over year due to demand for Axon Cloud software offerings and Axon Body 3, our latest generation camera that features LTE-connectivity and location-based services. International revenue grew 38% in the quarter to a record $30 million.

Gross margin increased both sequentially and year over year to 60.2%

Operating expenses of $89 million included $20 million in stock-based compensation expense and $6 million in costs related to the FTC litigation. (An update on FTC litigation is below, under “Update on Legal Matters.”)

GAAP EPS was $0.07 and Non-GAAP EPS was $0.40.

Quarterly Adjusted EBITDA of $30 million more than doubled year over year, representing a 20% margin on revenue, and delivering a 51% incremental contribution margin on revenue when compared with Q1 2019.

Cash and cash equivalents and investments totaled $395 million, including an investment payable of $13.5 million at March 31, 2020.

Uses of cash in the first quarter included $8.5 million tied to selling long-term hardware subscriptions, which results in recognizing revenue ahead of invoicing, $8.6 million tied to building up hardware inventory, which helped us respond to strong product demand while preparing us well to stagger factory work schedules due to COVID-19, and $4.7 million related to a strategic investment in Flock Safety.

Accounts payable of $32 million included the above mentioned $13.5 million payable, which settled in early April.

Axon has zero debt.

Financial commentary by segment:

TASER:


	THREE MONTHS ENDED									CHANGE
	31 MAR 2020			31 DEC 2019			31 MAR 2019			QoQ		YoY
	(in thousands)
Net sales	$	75,895		$	83,955		$	65,391		(9.6)	%	16.1	%
Gross margin		60.1	%		60.5	%		64.4	%	(40)	bp	(430)	bp

Segment revenue grew 16% year over year on strong demand for our cloud-connect TASER 7 device, and cartridges.

Gross margin of 60.1% reflects product mix and 100 basis points of incremental COVID-19 related manufacturing overhead.

Manufacturing employees who did not work, either due to belonging to a high risk group or to reduce the number of people in the factory to ensure adequate spacing and physical distancing, continued to receive payment. We incurred incremental expenses in Q1 2020 related to this decision, which included the cost of paying these employees in Q2 2020.

Through at least Q2 2020, TASER segment gross margin may continue to reflect COVID-19-related costs, including hazard pay, an on site nurse, extra cleaning, staggered shifts, and other precautionary measures to keep our workers safe.

Software & Sensors:


	THREE MONTHS ENDED									CHANGE
	31 MAR 2020			31 DEC 2019			31 MAR 2019			QoQ		YoY
	(in thousands)
Axon Cloud net sales	$	39,154		$	36,805		$	27,631		6.4	%	41.7	%
Axon Cloud gross margin		75.3	%		76.1	%		73.6	%	(80)	bp	170	bp

Sensors and Other net sales	$	32,113		$	51,091		$	22,788		(37.1)	%	40.9	%
Sensors and Other gross margin		42.0	%		27.0	%		28.4	%	1,500	bp	1,360	bp

Axon Cloud revenue grew 42% year over year to $39 million, driven by public safety adoption of our high-value, software-heavy bundles.

Axon Cloud gross margin of 75% includes some low-to-no margin professional services that support new installations for SaaS customers. The software-only revenue in this segment, which includes cloud storage and compute costs, has consistently carried a gross margin above 80%.

Sensors & other revenue grew 41% year over year due to strong demand and shipments of our Axon Body 3 camera.

Sensors & other gross margin was 42%. As a reminder, we manage toward a 25% gross margin for camera and sensors hardware, and the gross margin will fluctuate quarter to quarter depending on the customer mix.

Forward-Looking Performance Indicators:


	31 MAR 2020			31 DEC 2019			30 SEP 2019			30 JUN 2019			31 MAR 2019
	($in thousands)
Annual recurring revenue (1)	$	173,919		$	161,277		$	141,540		$	129,452		$	122,276
Total company future contracted revenue	$	1,274,000		$	1,230,000		$	1,130,000		$	1,050,000		$	930,000
Percentage of TASER devices sold on a recurring payment plan		43	%		58	%		55	%		60	%		42	%

(1)

Monthly recurring license, integration, warranty, and storage revenue annualized.

Annual Recurring Revenue grew 42% year over year to $174 million.

Total company future contracted revenue grew to $1.27 billion. This amount is limited to revenue from arrangements that meet the definition of a contract under Topic 606 as of March 31, 2020. We expect to recognize between 20% to 25% of this balance over the next 12 months and generally expect the remainder to be recognized over the following five to seven years, subject to risks related to delayed deployments, budget appropriation or other contract cancellation clauses.

The percentage of TASER devices sold on a subscription fell to 43% in the quarter because of the mix of units sold internationally, which has a lower subscription-adoption rate than the US.

Current market trends and outlook:

The following forward-looking statements reflect Axon’s expectations as of May 7, 2020, and are subject to substantial uncertainty due to the COVID-19 pandemic.

What we’re seeing in the market: To date, we are seeing mixed changes to buying habits among major US city police departments — some departments are continuing to place large orders for Axon products, and communicating gratitude that we are shipping mission critical equipment. We are seeing some agencies move to standard issue on Axon devices, to reduce sharing among officers, which has boosted orders.

A small number of agency customers have delayed their body camera programs, or postponed their subscription upgrades until unspecified later dates. Thus far, the impact of these COVID-19-related order delays to our full-year projections have been more than offset by a stronger-than-expected Q1 2020, better-than-expected international TASER orders realized through May 2020, and a strengthening Federal pipeline.

Through May, Axon has been executing upon orders from countries with which Axon has not historically done business, and this widening customer base is providing new revenue opportunities. So far in 2020, Axon has received body camera and TASER orders from Latin America, Asia, Southeast Asia, and South Asia — all representing new country markets — and we are also seeing stronger-than-average order activity in the UK.

We have also been encouraged by the speed with which the federal government has provided financial support to public safety. It is still early in the federal response, and the 2020 CARES Act contains $850 million in grants to state and local law enforcement, through the Edward Byrne Memorial Justice Assistance Grant (JAG), which is already more proactive than what we saw in the global economic recession of 2008-2009, as the first JAG grant then didn’t occur until 2009. In addition, the early phase COVID-19 stimulus packages included $150 million for federal law enforcement.

Withdrawing formal guidance: Given the number of factors outside of Axon’s control, we are withdrawing our

Caution on Use of Non-GAAP Measures

Although these non-GAAP financial measures are not consistent with GAAP, management believes investors will benefit by referring to these non-GAAP financial measures when assessing the Company’s operating results, as well as when forecasting and analyzing future periods. However, management recognizes that:

these non-GAAP financial measures are limited in their usefulness and should be considered only as a supplement to the Company’s GAAP financial measures;

these non-GAAP financial measures should not be considered in isolation from, or as a substitute for, the Company’s GAAP financial measures;

these non-GAAP financial measures should not be considered to be superior to the Company’s GAAP financial measures; and

these non-GAAP financial measures were not prepared in accordance with GAAP or under a comprehensive set of rules or principles.

Further, these non-GAAP financial measures may be unique to the Company, as they may be different from similarly titled non-GAAP financial measures used by other companies. As such, this presentation of non-GAAP financial measures may not enhance the comparability of the Company’s results to the results of other companies.

About Axon

Axon is a mission-driven company whose overarching goal is to protect life. Our vision is a world where bullets are obsolete, where social conflict is dramatically reduced, and where everyone has access to a fair and effective justice system. Axon is also a leading provider of body cameras for US law enforcement, providing more transparency and accountability to communities than ever before.

You may learn about our Environmental, Social, and Governance (ESG) and Corporate Social Responsibility (CSR) efforts by reading our ESG disclosure at investor.axon.com.

We work hard for those who put themselves in harm's way for all of us. More than 232,000 lives and countless dollars have been saved with the Axon network of devices, apps and people. Learn more at www.axon.com or by calling (800) 978-2737.

Facebook is a trademark of Facebook, Inc.; LTE is a trademark of the European Telecommunications Standards Institute; Twitter is a trademark of Twitter, Inc. and Zoom is a trademark of Zoom Video Communications, Inc. Axon, Axon Aware, Axon Accelerate, Axon Evidence, Axon Records, Axon Fleet, TASER, TASER 7 and the Delta Logo are trademarks of Axon Enterprise, Inc., some of which are registered in the US and other countries. For more information, visit www.axon.com/legal. All rights reserved.

Follow Axon here:

Axon on Twitter: https://twitter.com/axon_us

Axon on Facebook: https://www.facebook.com/Axon.ProtectLife/

Forward-looking statements

These forward-looking statements include, without limitation, statements regarding: the impact of the COVID-19 pandemic; proposed products and services and related development efforts and activities; expectations about the market for our current and future products and services; the impact of pending litigation; our outlook for 2020 with respect to revenue, legal expenses relating to the FTC litigation, stock compensation expense, and income tax rate; trends relating to subscription plan programs and revenues; our anticipation that contracts with governmental customers will be fulfilled; expected trends, including the benefits of, research and development investments; the sufficiency of our liquidity and financial resources; that we may repurchase our common stock; expectations about customer behavior; the impact on our investment portfolio of changes in interest rates; trends in the percentage of our revenues denominated in foreign currencies; our potential use of foreign currency forward and option contracts; statements concerning projections, predictions, expectations, estimates or forecasts as to our business, financial and operational results and future economic performance; statements of management’s strategies, goals and objectives and other similar expressions; as well as the

ultimate resolution of financial statement items requiring critical accounting estimates, including those set forth in our Form 10‑K for the year ended December 31, 2019. Such statements give our current expectations or forecasts of future events; they do not relate strictly to historical or current facts. Words such as “may,” “will,” “should,” “could,” “would,” “predict,” “potential,” “continue,” “expect,” “anticipate,” “future,” “intend,” “plan,” “believe,” “estimate,” and similar expressions, as well as statements in future tense, identify forward-looking statements. However, not all forward-looking statements contain these identifying words.

We cannot guarantee that any forward-looking statement will be realized, although we believe we have been prudent in our plans and assumptions. Achievement of future results is subject to risks, uncertainties and potentially inaccurate assumptions. The following important factors could cause actual results to differ materially from those in the forward-looking statements: the potential global impacts of the COVID-19 pandemic; our exposure to cancellations of government contracts due to appropriation clauses, exercise of a cancellation clause, or non-exercise of contractually optional periods; our ability to design, introduce and sell new products or features; our ability to defend against litigation and protect our intellectual property, and the resulting costs of this activity; our ability to manage our supply chain and avoid production delays, shortages, and impacts to expected gross margins; the impact of stock compensation expense, impairment expense, and income tax expense on our financial results; customer purchase behavior, including adoption of our software as a service delivery model; negative media publicity regarding our products; the impact of product mix on projected gross margins; defects in our products; changes in the costs of product components and labor; loss of customer data, a breach of security, or an extended outage, including our reliance on third party cloud-based storage providers; exposure to international operational risks; delayed cash collections and possible credit losses due to our subscription model; changes in government regulations in the U.S. and in foreign markets, especially related to the classification of our product by the United States Bureau of Alcohol, Tobacco, Firearms and Explosives and to evolving regulations surrounding privacy and data protection; our ability to integrate acquired businesses; our ability to attract and retain key personnel; and counter-party risks relating to cash balances held in excess of FDIC insurance limits. Many events beyond our control may determine whether results we anticipate will be achieved. Many events beyond our control may determine whether results we anticipate will be achieved. Should known or unknown risks or uncertainties materialize, or should underlying assumptions prove inaccurate, actual results could differ materially from past results and those anticipated, estimated or projected. You should bear this in mind as you consider forward-looking statements. Our Annual Report on Form 10-K lists various important factors that could cause actual results to differ materially from expected and historical results. These factors are intended as cautionary statements for investors within the meaning of Section 21E of the Exchange Act and Section 27A of the Securities Act. Readers can find them under the heading "Risk Factors" in the Annual Report on Form 10-K and in the Quarterly Report on Form 10-Q, and investors should refer to them. You should understand that it is not possible to predict or identify all such factors. Consequently, you should not consider any such list to be a complete set of all potential risks or uncertainties.

Except as required by law, we undertake no obligation to publicly update forward-looking statements, whether as a result of new information, future events or otherwise. You are advised, however, to consult any further disclosures we make on related subjects in our Form 10-Q, 8-K and 10-K reports to the SEC.

Update on Legal Matters:

Digital Ally v. Axon

On April 22, 2020, the Federal Circuit Court of Appeals (No. 19-2065) affirmed the Kansas district court’s non-infringement ruling and entered judgment on Digital's appeal in favor of Axon. This ruling effectively ends this litigation filed in January 2016. Digital had claimed that Axon’s Signal Technology infringed its ’452 Patent. The court of appeals ruling may be found at https://www.axon.com/legal.

Axon v. FTC

Axon continues to both vigorously prosecute its Federal court case against the FTC and defend the FTC's separate administrative action against the company. Presently, the FTC's administrative action has been stayed until June 3, 2020, due to the COVID-19 pandemic, and the hearing has been rescheduled to September 9, 2020. Separately, Axon's case against the FTC was dismissed on April 8, 2020, without prejudice, for lack of jurisdiction, holding that Axon must first bring its constitutional claims through the FTC's administrative process. Axon has appealed that ruling to the Ninth Circuit Court of Appeals (No. 20-15662), which has granted expedited consideration and set oral argument for July 17, 2020. A copy of Axon's appellate brief can be found on Axon's FTC Investor Briefing page at https://www.axon.com/ftc. Please visit https://investor.axon.com,

AXON ENTERPRISE, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

(in thousands, except per share data)


	THREE MONTHS ENDED
	31 MAR 2020		31 DEC 2019		31 MAR 2019
Net sales from products	$	107,288	$	134,497	$	88,089
Net sales from services		39,874		37,354		27,721
Net sales		147,162		171,851		115,810
Cost of product sales		48,884		70,418		39,600
Cost of service sales		9,670		8,793		7,293
Cost of sales		58,554		79,211		46,893
Gross margin		88,608		92,640		68,917
Operating expenses:
Sales, general and administrative		63,027		78,281		42,892
Research and development		26,381		28,745		23,354
Total operating expenses		89,408		107,026		66,246
Income (loss) from operations		(800)		(14,386)		2,671
Interest and other income, net		941		2,486		2,313
Income (loss) before provision for income taxes		141		(11,900)		4,984
Provision for (benefit from) income taxes		(3,933)		479		(1,435)
Net income (loss)	$	4,074	$	(12,379)	$	6,419
Net income (loss) per common and common equivalent shares:
Basic	$	0.07	$	(0.21)	$	0.11
Diluted	$	0.07	$	(0.21)	$	0.11
Weighted average number of common and common equivalent shares outstanding:
Basic		59,609		59,374		58,914
Diluted		60,394		60,257		59,751

AXON ENTERPRISE, INC.

SEGMENT REPORTING

(Unaudited)

(dollars in thousands)


	THREE MONTHS ENDED									THREE MONTHS ENDED									THREE MONTHS ENDED
	31 MAR 2020									31 DEC 2019									31 MAR 2019
				Software									Software									Software
				and									and									and
	TASER			Sensors			Total			TASER			Sensors			Total			TASER			Sensors			Total
Net sales from products (1)	$	75,175		$	32,113		$	107,288		$	83,406		$	51,091		$	134,497		$	65,301		$	22,788		$	88,089
Net sales from services (2)		720			39,154			39,874			549			36,805			37,354			90			27,631			27,721
Net sales		75,895			71,267			147,162			83,955			87,896			171,851			65,391			50,419			115,810
Cost of product sales		30,248			18,636			48,884			33,144			37,274			70,418			23,278			16,322			39,600
Cost of service sales		—			9,670			9,670			—			8,793			8,793			—			7,293			7,293
Cost of sales		30,248			28,306			58,554			33,144			46,067			79,211			23,278			23,615			46,893
Gross margin		45,647			42,961			88,608			50,811			41,829			92,640			42,113			26,804			68,917
Gross margin %		60.1	%		60.3	%		60.2	%		60.5	%		47.6	%		53.9	%		64.4	%		53.2	%		59.5	%

Research and development		3,032			23,349			26,381			4,185			24,560			28,745			3,712			19,642			23,354

(1)

Software and Sensors “products” revenue consists of sensors, including on-officer body cameras, Axon Fleet cameras, other hardware sensors, warranties on sensors, and other products, and is sometimes referred to as Sensors and Other revenue.

(2)

Software and Sensors “services” revenue comprises sales related to the Axon Cloud, which includes Axon Evidence, cloud-based evidence management software revenue, other recurring cloud-hosted software revenue and related professional services, and is sometimes referred to as Axon Cloud revenue.

AXON ENTERPRISE, INC.

UNIT SALES STATISTICS

(Unaudited)

Units in whole numbers


	THREE MONTHS ENDED
	31 MAR	31 MAR	Unit	Percent
	2020	2019	Change	Change
TASER 7	11,430	8,835	2,595	29.4	%
TASER X26P	11,003	14,985	(3,982)	(26.6)
TASER X2	10,478	9,861	617	6.3
TASER Pulse and Bolt	3,261	1,253	2,008	160.3
Cartridges	873,364	616,517	256,847	41.7
Axon Body	39,864	25,848	14,016	54.2
Axon Flex	3,074	3,591	(517)	(14.4)
Axon Fleet	2,676	1,735	941	54.2
Axon Dock	5,297	4,994	303	6.1
TASER Cam	1,514	1,741	(227)	(13.0)

AXON ENTERPRISE, INC.

RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES

(Unaudited)

Dollars in thousands


	THREE MONTHS ENDED
	31 MAR 2020			31 DEC 2019			31 MAR 2019
EBITDA and Adjusted EBITDA:
Net income (loss)	$	4,074		$	(12,379)		$	6,419
Depreciation and amortization		2,881			3,165			2,800
Interest expense		7			19			6
Investment interest income		(693)			(1,760)			(2,003)
Provision for (benefit from) income taxes		(3,933)			479			(1,435)
EBITDA	$	2,336		$	(10,476)		$	5,787

Adjustments:
Stock-based compensation expense	$	20,195		$	48,300		$	7,905
Transaction costs related to investment in unconsolidated affiliate		833			—			—
Loss on disposal and abandonment of intangible assets		13			16			18
Loss on disposal and impairment of property and equipment, net		517			134			242
Costs related to FTC litigation		6,135			240			—
Adjusted EBITDA	$	30,029		$	38,214		$	13,952
Net income (loss) as a percentage of net sales		2.8	%		(7.2)	%		5.5	%
Adjusted EBITDA as a percentage of net sales		20.4	%		22.2	%		12.0	%

Stock-based compensation expense:
Cost of product and service sales	$	590		$	790		$	226
Sales, general and administrative		14,970			40,212			4,681
Research and development		4,635			7,298			2,998
Total	$	20,195		$	48,300		$	7,905

AXON ENTERPRISE, INC.

RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES - continued

(Unaudited)

Dollars in thousands


	THREE MONTHS ENDED
	31 MAR 2020		31 DEC 2019		31 MAR 2019
Non-GAAP net income:
GAAP net income (loss)	$	4,074	$	(12,379)	$	6,419
Non-GAAP adjustments:
Stock-based compensation expense		20,195		48,300		7,905
Loss on disposal and abandonment of intangible assets		13		16		18
Loss on disposal and impairment of property and equipment, net		517		134		242
Transaction costs related to investment in unconsolidated affiliate		833		—		—
Costs related to FTC litigation		6,135		240		—
Income tax effects		(7,837)		(11,863)		(2,016)
Non-GAAP net income	$	23,930	$	24,448	$	12,568


	THREE MONTHS ENDED
	31 MAR 2020		31 DEC 2019		31 MAR 2019
Non-GAAP diluted earnings per share:
GAAP diluted earnings per share	$	0.07	$	(0.21)	$	0.11
Non-GAAP adjustments:
Stock-based compensation expense		0.33		0.80		0.13
Loss on disposal and abandonment of intangible assets		0.00		0.00		0.00
Loss on disposal and impairment of property and equipment, net		0.01		0.00		0.00
Transaction costs related to investment in unconsolidated affiliate		0.01		-		-
Costs related to FTC litigation		0.10		0.00		-
Income tax effects		(0.13)		(0.20)		(0.03)
Non-GAAP diluted earnings per share (1)	$	0.40	$	0.40	$	0.21

Weighted average number of diluted common and common equivalent shares outstanding (in thousands)		60,394		60,257		59,751

(1)

The per share calculations for GAAP net income, Non-GAAP adjustments and Non-GAAP diluted earnings per share are each computed independently. Per share amounts may not sum due to rounding.

AXON ENTERPRISE, INC.

CONSOLIDATED BALANCE SHEETS

(in thousands)


	31 MAR 2020		31 DEC 2019
	(Unaudited)
ASSETS
Current Assets:
Cash and cash equivalents	$	156,540	$	172,250
Short-term investments		188,673		178,534
Accounts and notes receivable, net		147,945		146,878
Contract assets, net		43,959		38,102
Inventory, net		46,922		38,845
Prepaid expenses and other current assets		34,702		34,866
Total current assets		618,741		609,475

Property and equipment, net		43,065		43,770
Deferred tax assets, net		29,433		27,688
Intangible assets, net		11,929		12,771
Goodwill		24,752		25,013
Long-term investments		50,225		45,499
Long-term notes receivable, net of current portion		27,556		31,598
Long-term contract assets, net		12,293		9,644
Other assets		59,457		40,181
Total assets	$	877,451	$	845,639

LIABILITIES AND STOCKHOLDERS’ EQUITY
Current Liabilities:
Accounts payable		31,568		25,874
Accrued liabilities		36,404		45,001
Current portion of deferred revenue		119,827		117,864
Customer deposits		3,325		2,974
Other current liabilities		3,891		3,853
Total current liabilities		195,015		195,566

Deferred revenue, net of current portion		91,886		87,936
Liability for unrecognized tax benefits		4,173		3,832
Long-term deferred compensation		3,430		3,936
Deferred tax liability		342		354
Other long-term liabilities		23,015		10,520
Total liabilities		317,861		302,144

Stockholders’ Equity:
Preferred stock		—		—
Common stock		1		1
Additional paid-in capital		543,305		528,272
Treasury stock		(155,947)		(155,947)
Retained earnings		175,699		172,265
Accumulated other comprehensive loss		(3,468)		(1,096)
Total stockholders’ equity		559,590		543,495
Total liabilities and stockholders’ equity	$	877,451	$	845,639

AXON ENTERPRISE, INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)


	THREE MONTHS ENDED
	31 MAR 2020		31 DEC 2019		31 MAR 2019
Cash flows from operating activities:
Net income (loss)	$	4,074	$	(12,379)	$	6,419
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization		2,881		3,165		2,800
Loss on disposal and abandonment of intangible assets		13		16		18
Loss (gain) on disposal and impairment of property and equipment, net		517		134		242
Stock-based compensation		20,195		48,300		7,905
Deferred income taxes		(1,548)		(4,041)		577
Unrecognized tax benefits		341		389		307
Other noncash, net		1,156		1,005		896
Provision for expected credit losses		902		—		—
Change in assets and liabilities:
Accounts and notes receivable and contract assets		(9,700)		(8,333)		(21,994)
Inventory		(8,630)		1,399		(3,936)
Prepaid expenses and other assets		2,277		2,122		(3,152)
Accounts payable, accrued liabilities and other liabilities		(3,562)		18,495		(7,284)
Deferred revenue		4,499		(4,463)		3,232
Net cash provided by (used in) operating activities		13,415		45,809		(13,970)
Cash flows from investing activities:
Purchases of investments		(99,512)		(111,784)		(105,322)
Proceeds from call / maturity of investments		84,315		37,876		—
Purchases of property and equipment		(2,209)		(3,828)		(5,271)
Purchases of intangible assets		(45)		(76)		(162)
Proceeds of disposal from property and equipment		78		—		—
Investment in unconsolidated affiliate		(4,700)		—		—
Net cash used in investing activities		(22,073)		(77,812)		(110,755)
Cash flows from financing activities:
Proceeds from options exercised		28		8		100
Income and payroll tax payments for net-settled stock awards		(5,190)		(783)		(1,259)
Net cash used in financing activities		(5,162)		(775)		(1,159)
Effect of exchange rate changes on cash and cash equivalents		(1,890)		1,007		67
Net decrease in cash and cash equivalents and restricted cash		(15,710)		(31,771)		(125,817)
Cash and cash equivalents, beginning of period		172,355		204,126		351,027
Cash and cash equivalents, end of period	$	156,645	$	172,355	$	225,210

AXON ENTERPRISE, INC.

SELECTED CASH FLOW INFORMATION

(Unaudited)

(in thousands)


	THREE MONTHS ENDED
	31 MAR 2020		31 DEC 2019		31 MAR 2019
Net cash provided by (used in) operating activities	$	13,415	$	45,809	$	(13,970)
Purchases of property and equipment		(2,209)		(3,828)		(5,271)
Purchases of intangible assets		(45)		(76)		(162)
Investment in unconsolidated affiliate		(4,700)		—		—
Free cash flow, a non-GAAP measure	$	6,461	$	41,905	$	(19,403)

AXON ENTERPRISE, INC.

SUPPLEMENTAL TABLES

(in thousands)


	31 MAR 2020		31 DEC 2019
	(Unaudited)
Cash and cash equivalents	$	156,540	$	172,250
Short-term investments		188,673		178,534
Long-term investments		50,225		45,499
Investment payable		(13,451)		—
Total cash and cash equivalents and investments, net	$	381,987	$	396,283